Epidemiological study on association of uric acid to creatinine ratio with metabolic syndrome in middle-aged and elderly populationin Shanghai

Abstract

Abstract:

Objective:To undertake an epidemiological study onassociation between serum uric acid to creatinine ratio (UA/Cr) and metabolic syndrome (MS) in middle-aged and elderly populationin Shanghai.Methods:A cross-sectional study was conducted in 6 570 residents aged 40 years or older in Jiading District of Shanghai in 2014. All participants received standard questionnaire, anthropometric measurements, biochemical evaluation. MS was defined according to the international Diabetes Federation (IDF) criteria. Participants were divided into 4 groups according to the quartiles of UA/Cr, and the associations of UA/Cr with MA were investigated by multivariate logistic regression analysis.Results:A total of 6 414 participants were included in this study, of which 33 135 (52.7%) participants were diagnosed with MS. The blood Cr level was 77（70-87） mmol/L, bloodUA level was 314（267-372） mmol/L, UA/Cr level was 4.01（3.46-4.65）. The UA/Cr of 1^stquartile group was <1.0, the 2ndquartile group was 1.0≤ to<1.5, the 3^rdquartile group was 1.5≤ to<2.0, the 4th quartile group was ≥2.0. From 1^stUA/Cr quartile to 4^thUA/Cr quartile, the body mass index (BMI), waist circumference, blood pressure, serum triglyceride, total cholesterol, low-density lipoproteincholesterol, HOMA-IR level, and serum C-reactive protein level increased with the increase of UA/Cr level（P<0.01）; the prevalence of MS and its components also showed a trend of increase (P<0.01). The multivariate logistic regression analysis revealed that serum UA/Cr was positively associated with MS, hypertension, dyslipidemia, hyperglycemia, central obesity, and insulin resistance. Compared with 1^stquartile group, the risk of MS in 2nd quartile group, 3^rdquartile group and 4^thquartile group 4 were 1.15(0.96-1.38),1.36(1.14-1.64）,1.96(1.62-2.37）; the risk of hypertension were 1.04(0.86-1.25), 1.22(1.01-1.48), 1.33(1.09-1.62); the risk of central obesity were 1.06(0.86-1.31),1.26(1.02-1.56), 1.33(1.09-1.62); the risk of high TG were 1.29(1.08-1.54), 1.74(1.46-2.07), 2.81(2.35-3.36); the risk of low HDL were 0.93(0.77-1.13),1.35(1.12-1.61), 1.50(1.25-1.80); the risk of insulin resistance were 0.96(0.77-1.19),1.14(0.92-1.40), 1.81(1.48-2.22) (allP<0.01).Conclusions:Serum UA/Cr is significantly associated with MS in middle-aged and elderly populationin Shanghai. Serum UA/Cr could serve as a biomarker of MS, which contributes to early detection and thereby the intervention of metabolic syndrome and its associated diseases.

Key words:Serum uric acid to creatinine ratio,Metabolic syndrome,Middle-aged and elderly population

CLC Number:

R587.1

HOU Yanan, XUAN Liping, ZHAO Zhiyun, LI Mian, CHEN Yuhong, DAI Meng, XU Min, BI Yufang, WANG Weiqing, GAO Jinli. Epidemiological study on association of uric acid to creatinine ratio with metabolic syndrome in middle-aged and elderly populationin Shanghai[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 44-50.

Figures/Tables4

参数	组分1	组分2	组分3	组分4	P值
例数	1 603	1 604	1 604	1 603	/
年龄（岁）	62.6±9.2	62.2±8.7	62.2±8.6	62.1±8.6	0.230 0
BMI（kg/m²）	23.9±3.5	24.6±3.3	25.2±3.4	26.0±3.6	<0.000 1
腰围（cm）	81.1±10.2	82.6±10.1	84.3±9.6	86.5±10.3	<0.000 1
收缩压（mmHg）	133.9±18.1	139.9±17.7	135.0±16.5	136.2±16.8	0.000 3
舒张压（mmHg）	75.6±9.7	75.8±9.7	76.7±9.3	77.1±9.6	<0.000 1
空腹血糖（mmol/L）	6.21±1.71	6.10±1.43	6.08±1.37	6.17±1.33	0.040 0
胰岛素抵抗指数	1.60（1.10~2.40）	1.74（1.21~2.58）	1.93（1.32~2.81）	2.32（1.57~3.43）	<0.000 1
TG（mmol/L）	1.27（0.96~1.76）	1.44（1.08~1.96）	1.55 1.14~2.16）	1.87（1.31~2.69）	<0.000 1
LDL-C（mmol/L）	3.51±0.79	3.60±0.76	3.60±0.77	3.69±0.84	<0.000 1
HDL-C（mmol/L）	1.39±0.33	1.35±0.30	1.32±0.30	1.29±0.28	<0.000 1
TC（mmol/L）	5.17±0.99	5.25±0.95	5.27±0.98	5.41±1.12	<0.000 1
C反应蛋白（mg/L）	0.19（0.14~0.28）	0.21（0.16~0.30）	0.23（0.17~0.34）	0.26（0.19~0.40）	<0.000 1
饮食因素（食用频率×食用量）	32.3±17.6	33.3±19.6	32.6±16.8	32.5±16.5	0.450 0
MS[n（%）]	624（38.9）	744（46.4）	876（54.1）	1069（66.7）	<0.000 1
高血压病[n（%）]	1058（66.0）	1082（67.5）	1171（73.0）	1228（76.6）	<0.000 1
高三酰甘油血症[n（%）]	452（28.2）	579（36.1）	688（42.9）	927（57.8）	<0.000 1
低高密度脂蛋白血症[n（%）]	432（27.0）	457（28.5）	587（36.6）	648（40.4）	<0.000 1
高血糖症[n（%）]	938（58.5）	951（59.3）	954（59.5）	1061（66.2）	<0.000 1
中心性肥胖[n（%）]	622（38.8）	725（45.2）	881（54.9）	993（62.0）	<0.000 1
体力活动（MET-h/wk）	16.8（3.0~21.0）	15.0（4.5~21.0）	18.0（4.5~21.0）	15.0（3.0~21.0）	0.220 0
目前吸烟[n（%）]	314（19.6）	321（20.0）	300（18.7）	297（18.5）	0.670 0
目前饮酒[n（%）]	181（11.3）	212（13.2）	221（13.8）	292（18.2）	<0.000 1

参数	β±SE^②	P值
腰围（cm）	2.15±0.15	<0.000 1
BMI（kg/m²）	0.82±0.05	<0.000 1
收缩压（mmHg）	1.17±0.27	<0.000 1
舒张压（mmHg）	0.71±0.14	<0.000 1
空腹血糖（mmol/L）	-0.006±0.02	0.790 0
胰岛素抵抗指数^①	0.06±0.004	<0.000 1
TG^①（mmol/L）	0.06±0.003	<0.000 1
HDL-C（mmol/L）	-0.04±0.004	<0.000 1
LDL-C（mmol/L）	0.05±0.01	<0.000 1
TC（mmol/L）	0.08±0.02	<0.000 1
C反应蛋白^①（mg/L）	0.05±0.004	<0.000 1

模型	OR（95%CI）				趋势P值
模型	组分 1	组分2	组分3	组分4	趋势P值
MS
模型1	1.00	1.36（1.18~1.56）	1.89（1.64~2.17）	3.14（2.72~3.63）	<0.000 1
模型2	1.00	1.18（0.98~1.41）	1.44（1.20~1.73）	2.11（1.75~2.54）	<0.000 1
模型3	1.00	1.15（0.96~1.38）	1.36（1.14~1.64）	1.96（1.62~2.37）	<0.000 1
高血压病
模型1	1.00	1.07（0.92~1.24）	1.39（1.20~1.62）	1.69（1.44~1.97）	<0.000 1
模型2	1.00	1.04（0.87~1.25）	1.24（1.03~1.50）	1.36（1.12~1.65）	<0.000 1
模型3	1.00	1.04（0.86~1.25）	1.22（1.01~1.48）	1.33（1.09~1.62）	<0.000 1
高血糖症
模型1	1.00	1.03（0.90~1.19）	1.04（0.90~1.20）	1.39（1.20~1.60）	<0.000 1
模型2	1.00	1.05（0.89~1.24）	0.94（0.80~1.12）	1.22（1.02~1.45）	0.100 0
模型3	1.00	1.03（0.87~1.22）	0.90（0.76~1.07）	1.15（0.96~1.37）	0.360 0
中心性肥胖
模型1	1.00	1.30（1.13~1.50）	1.92（1.67~2.21）	2.57（2.23~2.96）	<0.000 1
模型2	1.00	1.08（0.88~1.38）	1.32（1.06~1.63）	1.40（1.12~1.74）	0.006 0
模型3	1.00	1.06（0.86~1.31）	1.26（1.02~1.56）	1.32（1.06~1.65）	0.004 0
低高密度脂蛋白血症
模型1	1.00	1.08（0.93~1.26）	1.56（1.35~1.82）	1.84（1.59~2.13）	<0.000 1
模型2	1.00	1.08（0.88~1.34）	1.32（1.06~1.63）	1.40（1.12~1.74）	<0.000 1
模型3	1.00	0.93（0.77~1.13）	1.35（1.12~1.61）	1.50（1.25~1.80）	<0.000 1
高三酰甘油血症
模型1	1.00	1.44（1.24~1.67）	1.91（1.65~2.22）	3.49（3.01~4.05）	<0.000 1
模型2	1.00	1.31（1.10~1.56）	1.80（1.51~2.14）	2.95（2.48~3.53）	<0.000 1
模型3	1.00	1.29（1.08~1.54）	1.74（1.46~2.07）	2.81（2.35~3.36）	<0.000 1
胰岛素抵抗
模型1	1.00	1.08（0.91~1.29）	1.46（1.23~1.73）	2.70（2.30~3.17）	<0.000 1
模型2	1.00	0.98（0.79~1.21）	1.19（0.97~1.47）	1.95（1.59~2.39）	<0.000 1
模型3	1.00	0.96（0.77~1.19）	1.14（0.92~1.40）	1.81（1.48~2.22）	<0.000 1

References24

[1]	Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary[J]. Crit Pathw Cardiol, 2005, 4(4):198-203.
[2]	Nejatinamini S, Ataie-Jafari A, Qorbani M, et al. Asso-ciation between serum uric acid level and metabolic syndrome components[J]. J Diabetes Metab Disord, 2015, 14:70.
[3]	Fu CC, Wu DA, Wang JH, et al. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients[J]. Acta Diabetol, 2009, 46(2):127-134.
[4]	Guo L, Cheng Y, Wang X, et al. Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality[J]. Acta Diabetol, 2012, 49(Suppl 1):S65-S71.
[5]	Mankovsky B, Kurashvili R, Sadikot. Is serum uric acid a risk factor for atherosclerotic cardiovascular disease? A review of theclinical evidence. Part 1. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 4, 2010:176-184.
[6]	Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid[J]. Nucleosides Nucleotides Nucleic Acids, 2008, 27(8):967-978.
[7]	Norvik JV, Storhaug HM, Ytrehus K, et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study[J]. BMC Cardiovasc Disord, 2016, 16:85.
[8]	Culleton BF, Larson MG, Evans JC, et al. Prevalence and correlates of elevated serum creatinine levels: the Framin-gham Heart Study[J]. Arch Intern Med, 1999, 159(15):1785-1790.
[9]	Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey(1988-1994)[J]. Arch Intern Med, 2001, 161(9):1207-1216.
[10]	Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States[J]. J Am Soc Nephrol, 2002, 13(3):745-753.
[11]	Al-Daghri NM, Al-Attas OS, Wani K, et al. Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients[J]. Sci Rep, 2017, 7(1):12104.
[12]	Kim ES, Kwon HS, Ahn CW, et al. Serum uric acid level is associated with metabolic syndrome and microalbumi-nuria in Korean patients with type 2 diabetes mellitus[J]. J Diabetes Complications, 2011, 25(5):309-313.
[13]	Sah SK, Khatiwada S, Pandey S, et al. Association of high-sensitivity C-reactive protein and uric acid with the metabolic syndrome components[J]. Springerplus, 2016, 5:269.
[14]	Gu L, Huang L, Wu H, et al, R. Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disea-se in type 2 diabetes mellitus patients with preserved kidney function[J]. Diab Vasc Dis Res, 2017, 14(3):221-225.
[15]	Vincent MA, Barrett EJ, Lindner JR, et al. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin[J]. Am J Physiol Endocrinol Metab, 2003, 285(1):E123-E129.
[16]	Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome[J]. Cleve Clin J Med, 2006, 73(12):1059-1064.
[17]	Kaur J. A comprehensive review on metabolic syndrome[J]. Cardiol Res Pract, 2014, 2014:943162.
[18]	Kawamoto R, Tabara Y, Kohara K, et al. Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women[J]. Endocrine, 2013, 44(1):132-139.
[19]	Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperu-ricemia and incidence of hypertension among men without metabolic syndrome[J]. Hypertension, 2007, 49(2):298-303.
[20]	Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity[J]. Metabolism, 1998, 47(8):929-933.
[21]	Schmidt MI, Watson RL, Duncan BB, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators[J]. Metabolism, 1996, 45(6):699-706.
[22]	Eräranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency[J]. J Hypertens, 2008, 26(8):1661-1668.
[23]	Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk[J]. N Engl J Med, 2008, 359(17):1811-1821.
[24]	Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration[J]. JAMA, 1991, 266(21):3008-3011.